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ABSTRACT
The folate and methionine metabolism play essential roles in DNA synthesis and DNA methylation, hence their metabolic
pathways might affect the susceptibility to diseases such as leukaemia. In this study, we examined the frequencies of
several folate-related genes polymorphisms such as methylenetetrahydrofolate reductase MTHFR C677T and A1298C,
methylenetetrahydrofolate dehydrogenase1 MTHFD1 G1958A, methionine synthase MTR A2756G and reduced folate
carrier RFC1 G80A in 131 childhood leukaemia patients using PCR and PCR-RFLP techniques and determined their
association with the risk of developing childhood leukaemia. An increased occurrence of childhood leukaemia was
associated with MTHFR 677 CT (OR = 7.22; 95 % CI, 2.98-17.50), MTHFR 1298 AC (OR: 27.92 95% CI: 9.89-78.83)
and MTHFR 1298 CC (OR: 13.25 95% CI: 4.42-39.73), RFC1 80 GA (OR: 3.95 95% CI: 1.58-9.83), RFC1 80 AA (OR:
3.83, 95% CI: 1.4-10.26), and SHMT1 1420 CT variant (OR: 5.89, 95% CI: 2.7-12.81) (p < 0.05). On the other hand,
MTHFD1 1958 GA (OR = 0.42; 95 % CI, 0.20-0.90; p = 0.03) and MTRR 66 GG variant (OR = 0.05; 95 % CI, 0.01-0.29;
p < 0.001) were associated with reduced risk of developing childhood leukaemia. There were no significant association
of TS 3R variant and MTR 2576 A > G with the risk of childhood leukaemia variant among the 131 childhood leukaemia
patients.
INTRODUCTION
Childhood leukaemia represents 4.7 % of the childhood
cancers in the Malaysian population (1). Many factors are
involved in leukaemogenesis such as genes and
environment interaction (2), maternal consumption of folate
(3), or changes in DNA that could lead to uncontrolled
cellular growth (4). Folate metabolism may become
deranged by inadequate nutrition, altered cellular transport,
and polymorphisms in folate-related genes (5). Folate is
crucial in DNA synthesis and repair where folate deficiency
may influence the risk of cancer (6) through mis-
incorporation of uracil leading to double strand breaks,
chromosomal damage and DNA hypomethylation or
dysmethylation (7).
Polymorphisms in folate-related genes listed in Figure
1 have been described and reported to play an essential
role in leukaemia susceptibility (5). Reduced folate carrier
(RFC) transport mutations have been identified that alter
or disrupt RFC expression, resulting in a major loss of
antifolate uptake. In ALL, low levels of human RFC have
been shown to be associated with poor prognosis (9).
Methylene tetrahydrofolate reductase (MTHFR)
polymorphism 677 C > T and 1298 A > C alters normal
intracellular folate distribution. Lower activity of MTHFR
could lead to increase plasma levels of homocysteine and
decrease the formation of methyl-THF that could lead to
the pooling of methylene-THF, the methyl group donor for
dUMP to dTMP conversion. Therefore, lower activity of
MTHFR might favor optimal DNA synthesis by reducing
uracil and mis-incoporation rate during uracil excision
repairing processes (7, 8). Both MTHFR 1298 and MTHFR
677 polymorphisms were reported to decrease the
susceptibility towards lymphoid leukaemia in children and
adults (2, 6, 8, 10, 11, 12, 13). As an enzyme that catalyzes
the re-methylation of homocysteine to methionine via
cobalamin and folate dependent reaction, methionine
synthase reductase (MTRR) plays a crucial role in
maintaining the active form of cobalamin. The 66 A to G
MTRR polymorphisms have a significant influence on the
total circulating homocysteine concentration (14).
Methylene tetrahydrofolate dehydrogenase1 (MTHFD1)
plays an important role in the metabolism of folate and
homocysteine, and polymorphisms of MTHFD1 may result
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Figure 1: Intracellular metabolism of folate. For clarity, the reaction catalysed by methylenetetrahydrofolate dehydrogenase/
methenyltetrahydrofolate cyclohydrolase/ formyltetrahydrofolate synthetase (MTHFD1) is not shown. MTHFD1 converts
CH2-THF in 3 steps and provide formyl-THF (CHO-THF) for purine synthesis. THF indicates tetrahydrofolate; DHF,
dihydrofolate; CH2-THF, methylene-THF; CH3-THF; methyl-THF; SAM, S-adenosylmethionine; SAH,
S-adenosylhomocysteine; dTMP, deoxy thymidine monophosphate; dUMP, deoxy uridine monophosphate; TS, thymidylate
synthase; MTHFR, methylenetetrahydrofolate reductase; MS, methionine synthase; MTRR, methionine synthase reductase;
SHMT, serine-hydroxymethyltransferase; DHFR, dihyrdofolate reductase; RFC, reduced folate carrier; MTX-PG,
methotrexate-polyglutamate; and NADP, nicotinamide adenine dinucleuotide
in disturbance of the folate-mediated homocysteine
pathway. In 2006, De Marco et al reported that
heterozygosity and homozygosity of MTHFD1 1958 gene
polymorphism as one of the contributing genetic factors
for neural tube defect in the Italian population. However,
the role of MTHFD1 gene and other folate related genes
and in childhood leukaemia susceptibility still remains
unclear (15).
Patients with serine hydroxymethyl transferase
(SHMT1 1420T allele) polymorphisms in combination with
thymidilate synthase gene (TS) repeat (3R) polymorphisms
appeared to have a lower risk of ALL (16, 17). Methionine
synthase (MTR 2756G) has been reported to be a risk allele
for acute lymphoblastic leukaemia (ALL) on its own or in
combination with the MTHFR 677 T allele in adults (2).
However, it reduces the risk of ALL in adults when combined
with the SHMT1 1420 CT/TT variant (16). The aim of this
study was to investigate the frequency of folate-related
genes polymorphisms in a population of Malaysian
childhood leukaemia patients and the interaction of these
genes with the risk of childhood leukaemia. We
hypothesised that the derangements of folate status caused
by the polymorphisms involving folate-related genes and
their interactions would influence childhood leukaemia
susceptibility.
MATERIALS AND METHODS
SUBJECT RECRUITMENT
A total of 131 patients with childhood leukaemia were
recruited. Ninety-three of them were patients treated at the
Universiti Kebangsaan Malaysia Medical Centre (UKMMC)
and another 38 patients were from the Paediatric Institute
of the Hospital Kuala Lumpur (HKL). All these patients
underwent treatment between the year 2000 to 2008. A total
of 150 controls were selected from students attending form
two (14 years of age) at the Sekolah Menengah
Kebangsaan Wangsa Maju and Sekolah Menengah
Kebangsaan Taman Melati Setapak during the year 2005.
Informed consent was obtained from the legal guardian for
each subject and control. This study was approved by the
ethic committee of all participating institutions. Peripheral
blood samples were taken from the cases and buccal swabs
were taken from the controls. Samples were stored at -80°C
before DNA extraction and analysis. The age range of the
leukaemia patients were 9 month to 19 years old. There
were 114 patients with acute lymphoblastic leukaemia (ALL),
5 with acute myeloid leukaemia (AML), and 12 with relapsed
ALL. The controls were 14 years old when their blood
samples were taken (2005).
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DNA EXTRACTION
DNA from the peripheral blood samples taken from cases
was extracted using the salt saturation method. DNA from
buccal swabs of the controls was extracted using the
BuccalAmp™ DNA Extraction Kit QuickExtract™ DNA
Extraction Solution 1.0 Catch-All™ Sample Collection
Swabs.
GENOTYPE ANALYSIS OF FOLATE-RELATED GENE
POLYMORPHISMS
Polymerase chain reaction (PCR) amplifications of the
genetic variant of each folate-related gene were carried out
using forward and reverse primers listed in Table 1.
The polymorphisms for each gene were determined
by PCR-restriction fragment length polymorphisms (RFLP)
using Hinf I restriction enzyme for MTHFR C677T
Table 1. List of oligonucleotide forward and reverse primer for each gene in the polymerase chain reaction (PCR)
Gene Forward and reverse primer
MTHFR (C677T) Forward primer: 5’-TGAAGGAGAAGGTGTCTGCGGGA-3’
Reverse primer: 5’-AGGACGGTGCGGTGAGAGTG-3’
MTHFR (A1298C) Forward primer: 5’-CTTTGGGGAGCTGAAGGACTACTAC-3’
Reverse primer: 5’-CACTTTGTGACCATTCCGGTTTG-3’
RFC (G80A) Forward primer: 5’-AGTGTCACCTTCGTCCCCTC-3’
Reverse primer: 5’-CTCCCGCGTGAAGTTCTT-3’
TS (3R) Forward primer: 5’- GTGGCTCCTGCGTTTCCCCC -3’
Reverse primer: 5’CCAAGCTTGGCTCCGAGCCGGCCACAGGCATGG-3’
SHMT1 (C1420T) Forward primer: 5’-CAGAGCCACCCTGAAAGAGTTC-3’
Reverse primer: 5’-GTGGGCCCGCTCCTTTA-3’
MTR (A2756G) Forward primer: 5’-TGTTCCAGACAGTTAGATGAAAATC-3’
Reverse primer: 5’-GATCCAAAGCCTTTTACACTCCTC-3’
MTRR (A66G) Forward primer: 5’- GCAAAGGCCATCGCAGAAGACAT-3’
Reverse primer: 5’-TGGTGGTATTAGTGTCCTTTTG-3’
MTHFD1 (G1958A) Forward primer: 5’-CCCACTTTGAAGCAGGATTG-3’
Reverse primer: 5’-CACCATCCCAATTCCCCTGATG-3’
polymorphisms, Mbo II for MTHFR A1298C
polymorphisms, Hha I for RFC A80G polymorphisms, Ear
I for SHMT C1420T polymorphisms, Hae III for MTR
A2756G polymorphisms, Nde I for MTRR A66G
polymorphisms and Msp I for MTHFD G1958A
polymorphisms. As for the 28-bp double (2R2R) or triple
tandem repeats (3R3R) in the promoter region of thymidylate
synthase (TS), the resulting bands were directly visualized
on agarose gels after PCR (18).
DNA sequencing was used to validate the
polymorphisms for each folate-related gene. Sequence of
each polymorphism was determined using the 3130 × l
Applied Biosystem (ABI) Genetic Analyzer with
BigDye®Terminator v3.1 Cycle Sequencing Kit.
STATISTICAL ANALYSIS
Power calculation was performed using the BRIDGES power
and sample size calculation program (19). Logistic
regression analysis was performed to obtain odd ratios
(ORs) and 95% confidence intervals (CI) for the estimation
of the relative risks for each polymorphism. Gene-gene
interactions within the folate-related genes polymorphism
were also explored. All analyses with dominant genetic
model were carried out using the SPSS version 16.0 to
calculate ORs and CIs.
RESULTS
Of the the 131 patients, 54.2% were female, and 45.8% were
male with an ethnicity distribution of 75.6% Malays, 15.3%
Chinese and 9.7% Indians (Table 2) with the majority of
patients were ALL (88.5%), followed by relapsed ALL (6.1%)
and acute myeloid leukaemia (AML) (3.8%).
Table 3 shows the distribution between folate-related
gene polymorphisms in childhood leukaemia patients and
controls. The MTHFR 677 CT variant was significantly
more common in the childhood leukaemia group (39.7%)
compared with the control group, indicating that the
MTHFR 677 CT variant is related to increased risk of
childhood leukaemia (OR = 7.22; 95 % CI, 2.98-17.50; p <
0.00) in our population.
The frequency of MTHFR 1298 AA homozygous
dominant genotype was lower in patients (6.1%) compared
with the control group (50.7%). Significant increased risk
was also observed for MTHFR 1298 AC (OR = 27.92; 95%
CI, 9.89-78.83; p < 0.00), and MTHFR 1298 CC variant (OR
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Table 3. Distribution of folate related genes in childhood leukaemia patients and control
Genotype Childhood Leukaemia n = 131 (%) Control n = 150 (%) OR (95% CI) p value
MTHFR 677 CC 74 (56.5) 120 (80) 1
CT 52 (39.7) 21 (14.0) 7.22 (2.98-17.50) 0.00
TT 5 (3.8) 9 (6.0) 1.63 (0.33-3.31) 0.55
MTHFR 1298 AA 8 (6.1) 76 (50.7) 1
AC 93 (71.0) 40 (26.7) 27.92 (9.89-78.83) 0.00
CC 30 (22.9) 34 (22.7) 13.25 (4.42-39.73) 0.00
RFC1 80 GG 18 (13.7) 49 (32.7) 1
GA 62 (47.3) 61 (40.7) 3.95 (1.58-9.83) 0.00
AA 51 (38.9) 40 (26.6) 3.83 (1.43-10.26) 0.01
TS 3R 91 (69.5) 86 (57.3) 1
3R2R 32 (24.4) 51 (34.0) 0.49 (0.22-1.09) 0.08
2R 8 (6.1) 13 (8.7) 1.26 (0.34-4.36) 0.73
SHMT1 1420 CC 54 (41.2) 85 (56.7) 1
CT 74 (56.5) 38 (25.3) 5.89 (2.7-12.81) 0.00
TT 3 (2.3) 27 (18.0) 0.43 (0.10-1.78) 0.24
MTHFD1 1958 GG 68 (51.9) 45 (30.0) 1
GA 44 (33.6) 85 (56.7) 0.42 (0.20-0.90) 0.03
AA 19 (14.5) 20 (13.3) 0.43 (0.15-1.27) 0.13
MTR 2756 AA 98 (74.8) 98 (65.3) 1
AG 32 (24.4) 47 (31.3) 0.85 (0.39-1.85) 0.68
GG 1 (0.8) 5 (3.3) 0.24 (0.02-3.31) 0.28
MTRR 66 AA 30 (22.9) 17 (11.3) 1
AG 98 (74.8) 115 (76.7) 0.38 (0.14-1.02) 0.06
GG 3 (2.3) 18 (12.0) 0.05 (0.01-0.29) 0.00
Table 2. Demographic data for 131 childhood leukaemia patients and 150 childhood control
Race Gender
Chinese (%) Malay (%) Indian (%) Male (%) Female (%)
Control 2 (1.3) 134 (89.3) 14 (9.3) 37 (24.7) 113 (75.3)
Childhood leukaemia 20 (15.3) 99 (75.6) 12 (9.7) 60 (45.8) 71 (54.2)
Total 22 (7.8) 233 (82.9) 26 (9.3) 97 (34.5) 184 (65.5)
= 13.25, 95% CI, 4.42-39.73, p < 0.00) in childhood leukaemia
patients compared to the control group.
The frequencies of the RFC1 80 GA variant and RFC
80 AA variant in childhood leukaemia patients were higher
(47.3% and 38.9%) compared with the control group (40.7%
and 26.7%), indicating that RFC1 80 GA variant (OR = 3.95;
95% CI, 1.58-9.83; p < 0.00) and RFC1 80 AA variant (OR =
3.83; 95% CI, 1.43-10.26; p < 0.00) could be related to an
increased risk of leukaemia. There is also an increased risk
of leukaemia for patients having the SHMT1 1420 CT variant
(OR = 5.89; 95% CI, 2.7-12.81; p < 0.00).
The MTHFD1 1958 GA (OR = 0.42; 95% CI, 0.20-0.90;
p = 0.03) and MTRR 66 GG variants (OR = 0.05; 95% CI,
0.01-0.29; p < 0.00) were associated with a decreased risk of
leukaemia in the population.
We also analysed the gene-gene interaction between
the MTHFR 677 CT (Table 4), MTHFR 1298 AC (Table 5)
and other folate-related gene polymorphisms. In order to
look for allele interaction, we combined the frequencies of
homozygous mutants and heterozygous variants in the
analysis. We observed that the interaction between MTHFR
677 CC variant with MTHFR 1298 AC variant (OR = 11.9;
95% CI, 4.8-29.3), MTHFR 1298 CC variant (OR = 4.2; 95%
CI, 1.6-11.2), MTHFD 1958 GA (OR = 2.82; 95% CI, 2.09-
7.3), RFC1 80 GA variant (OR = 2.9; 95% CI, 1.2-7.3) and
RFC1 80 AA variant (OR = 5.14; 95% CI, 2.01-13.2) all
suggested an increased risk of leukaemia (Table 4). There
is also an interaction between MTHFR 677 CT and TT
variant with RFC1 80 GG variant (OR = 4.8; 95% CI, 1.7-
14.2) indicating an increased leukaemia risk.
The interaction between MTHFR 1298 AC and CC
variant with MTRR 66 AA (OR = 30.7; 95% CI, 3.9-239),
MTRR 66 AG (OR = 11.4; 95% CI, 1.9-66.5) and SHMT 1420
CT (OR = 15.1; 95% CI, 3.1-72.7) also suggested an increased
leukaemia risk as shown in Table 4.
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Table 4. Interaction between MTHFR 677 polymorphisms and other polymorphisms in folate related genes in control
and childhood leukemia
Genotype Control (n) Childhood patients (n) OR (CI) p value
MTHFR677 CC v/s
MTHFR1298 AA 55 7 1 0
AC 33 50 11.9 (4.8-29.3) 0*
CC 32 17 4.2 (1.6-11.2) 0.04*
MTHFD 1958 GG 34 43 1 0.1
GA 7 25 2.82 (2.09-7.3) 0.03*
AA 4 0 N/A
MTR 2756 AA 81 53 1 0.77
AG 36 20 0.85 (0.45-1.62) 0.62
GG 3 1 0.51 (0.52-5.03) 0.56
MTRR 66 AA 12 16 1 0.14
AG 92 56 0.46 (0.20-1.04) 0.61
GG 16 2 0.09 (0.02-0.49) 0.00*
RFC GG 34 7 1 0.00
GA 52 31 2.9 (1.2-7.3) 0.02*
AA 34 36 5.14 (2.01-13.2) 0.00*
SHMT 1420 CC 67 17 1
CT 30 55 7.23 (3.6-14.5) 0*
TT 23 2 0.34 (0.1-1.5) 0.17
TS 3R 68 44 0.85
3R2R 42 23 0.85 (0.45-0.6) 0.61
2R 10 7 1.08 (0.4-3.1) 0.88
MTHFR 677 CT+TT v/s 
MTHFR1298 AA 21 1 0.95 (0.2-5.1) 0*
AC 7 43 0.007 (0.001-0.09) 0*
CC 2 13 1 0.95
MTHFD 1958 GG 11 25 2.02 (0.62-6.6) 0.3
GA 11 23 1.9 (0.56-6.1) 0.3
AA 8 9 1 0.5
MTR 2756 AA 17 45
AG 11 12
GG 2 0 N/A
MTRR 66 AA 5 14 5.6 (0.4-76.05) 0.2
AG 23 42 3.7 (0.3-42.5) 0.3
GG 2 1 1 0.41
RFC GG 15 22 4.8 (1.7-14.2) 0.04*
GA 9 32 3.4 (1.0-11.6) 0.05
AA 6 15 1 0.12
SHMT 1420 CC 18 37 8.2 (0.86-79) 0.07
CT 8 19 9.5 (0.9-98.8) 0.06
TT 4 1 1 0.16
TS 3R 18 47 7.8 (0.76-80.3) 0.08
3R2R 9 9 3 (0.26-34.6) 0.38
2R 3 1 1 0.07
* p < 0.05
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Table 5. Interaction between MTHFR 1298 polymoprhisms and other folate related genes in control and childhood leukemia
Genotype Childhood control (n) Childhood leukemia (n) OR (CI) p value
MTHFR 1298 AA v/s
MTHFR677 CC 55 7 0.87
CT 14 1 0.56 (0.06-4.9) 0.6
TT 7 0 N/A
MTHFD 1958 GG 22 5 0.27
GA 46 3 0.29 (0.06-1.3) 0.11
AA 8 0 N/A
MTR 2756 AA 48 7 0.52
AG 24 1 0.29 (0.03-2.5) 0.25
GG 4 0 N/A
MTRR 66 AA 12 2 0.9
AG 57 5 0.65 (0.05-8.2) 0.7
GG 7 1 0.88 (0.03-25.6) 0.9
RFC GG 24 2 0.53
GA 34 5 0.4 (0.03-5.6) 0.5
AA 18 1 0.2 (0.01-4.2) 0.3
SHMT 1420 CC 40 4 0.3
CT 20 5 3.3 (0.7-15.4) 0.12
TT 16 0 N/A
TS 3R 41 5 0.22
3R2R 29 1 0.28 (0.03-2.6) 0.26
2R 6 2 2.7 (0.4-17.4) 0.29
MTHFR 1298 AC+CC v/s
MTHFR 677 CC 65 68 0.23 (0.03-1.6) 0.14
CT 7 51 5.1 (0.6-42.8) 0.13
TT 2 5 0
MTHFD 1958 GG 23 63 2.4 (0.7-8.1) 0.2
GA 39 41 0.91 (0.3-3) 0.9
AA 12 19 0.09
MTR 2756 AA 50 91 2.3 (0.1-56.6) 0.6
AG 33 31 2.45 (0.1-64.6) 0.6
GG 1 1 0.87
MTRR 66 AA 5 28 30.7 (3.9-239) 0*
AG 58 93 11.4 (1.9-66.5) 0.01*
GG 11 2 0
RFC GG 25 16 0.15 (0.05-0.5) 0*
GA 27 57 0.83 (0.33-2.1) 0.68
AA 22 50 0
SHMT 1420 CC 45 51 2.2 (0.5-10.4) 0.31
CT 18 69 15.1 (3.1-72.7) 0*
TT 11 3 0
TS 3R 45 86 2.2 (0.7-7) 0.17
3R2R 22 31 1.6 (0.5-5.6) 0.42
2R 7 1 0.31
* p < 0.05
DISCUSSION
Leukaemia is one of the most prevalent childhood cancers
worldwide and also in Malaysia (1). Onset at a young age
and a short latency period between the appearance of
mutations and identification of tumor cells are unique to
childhood leukaemia patients (20).
Distribution of MTHFR polymorphisms differs
between ethnic groups as we observed a high frequency
of MTHFR 1298 variant AC (71%) in our population of
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childhood leukaemia patients compared with the Filipino
population (47.7%) (21). However, the frequency of MTHFR
677 T-allele (43.5%) is lower compared with Japanese
population (66.7%) (12). Among the ethnic groups in
Malaysia, we observed different distributions of MTHFR
in the Indian population (9.2%), Chinese (7.8%) and Malay
(83%).
From a previous study, the MTHFR 677 TT and
MTHFR 1298 CC variants were reported to decrease the
risk of colorectal cancer (22). Various studies reported both
MTHFR variants to decrease the susceptibility to lymphoid
leukaemia in children and adults (2, 6, 11, 12, 13). Using a
recessive model, we observed that the T-allele of MTHFR
677 decreased the leukaemia risk (OR = 0.33; 95% CI, 0.19-
0.55) in children. According to a meta-analysis done by
Robien et al., in 2003, many studies have shown that
MTHFR 677TT decreased leukaemia risk especially in
childhood ALL (23). However, the relationship between
MTHFR 1298 variant with childhood leukaemia is still
controversial. In Korean populations, there is interaction
between MTHFR 677 CC variant and MTHFR 1298 CC
variant in chronic myeloid leukaemia (CML), acute myeloid
leukaemia (AML), and multiple myeloma (MM) population
(p < 0.05) (24) .
The polymorphisms of MTHFR 1298 AC and CC
variants were higher in our patients compared to the control
group indicating the role of this polymorphism in increasing
leukaemia risk in childhood. This finding concurred with
the study done in the Philippines (21). We also observed
that the interaction between MTHFR 677 and MTHFR 1298
with other folate-related genes increased leukaemia risk
especially in patients who presented with the combination
alelle variant of MTHFR 677 CC and MTHFR 1298 CC (22).
Theoretically, lower activity of MTHFR will lead to
pooling of methylene tetrahydrofolate (methylene-THF) that
will enhance the fidelity of DNA synthesis. The increases
in the methylene-THF pool leads to an increase in the
availability of methyl groups for the conversion of uracil to
thymidine, causing less mis-incorporation of uracil than
otherwise that might have if there was inadequate
thymidine for DNA synthesis (25, 26). Taking it all together,
it is postulated that the relationship between MTHFR
polymorphism and the risk of cancer is modifiable by other
nutrients involved in the MTHFR metabolic pathway. It is
also speculated that during times of high supply of dietary
methyl, the 677TT polymorphism confers a protective effect
by way of a higher intracellular methylene-THF pool.
However, when dietary folate is low and presence of methyl-
THF is depleted by high alcohol consumption, the
protective effect of 677TT is abolished. The reduction of
the methylene-THF pool will then lead to abnormal DNA
synthesis. Methylation in this case would also be another
mechanism by which carcinogenesis appears, since the
methyl-THF pool would have been depleted by poor supply
and the influence of the 677TT polymorphism (25). For that
reason, it must be appreciated that the gene-nutrient
interaction in the MTHFR polymorphism-folate scenario is
not straightforward.
As for RFCs that play a role as folate transporter,
distribution of RFC1 80 variant in a Japanese 281 childhood
case-control group showed highest distribution among
heterozygous mutants (43.8%) compared with other
genotypes (27). De Marco in 2001, reported almost the same
distribution of this heterozygous mutant genotype in
patients with neural tube defects in Italy (28). In our study,
RFC polymorphisms seemed to be related to an increased
risk of childhood leukaemia. The RFC transport system
plays pivotal roles as methotrexate (MTX) (29) and folate
transporters hence the effectiveness of chemotherapy with
these agents is closely linked to the levels and activity of
RFC transport in both tumors and normal tissues (30, 31).
The RFC1 80 AA polymorphism was observed to increased
MTX transport in plasma indicating effective
transportation of MTX for the variant (27). However, this
study did not elucidate the relationship between the
transport system and the development of leukaemia.
The TS gene regulation occurs not only at the
transcriptional level but also at the translation level (18).
The TS is an important target for a variety of
chemotherapeutic agents including 5-fluorouracil (5-FU),
5-FU prodrugs (capecitabine), and novel folate-based TS
inhibitors (raltitrexed and pemetrexed) which are used for
colorectal and other solid tumors treatment (32). The TS
alleles polymorphisms are represented by 28-based pair
tandem double or triple repeats, creating genotypes defined
as 2R/2R, 2R/3R and 3R/3R respectively. The TS genes
with the 3R allele were found to have greater expression
activities than the 2R sequence in a transient expression
assay in cancer cells (18). Taken together, the
polymorphisms might have altered TS gene expression (18)
and translation efficiency (33).
In our study, 69.5% of the childhood leukaemia group
carried the 3R variant compared to 57.3 % in the control
group, and this difference is not significant (p = 0.64). Non-
significant difference in distribution of TS polymorphisms
was observed in a Japanese study (23). Skibola et al. (16) in
2002 and de Jonge et al in 2009 (5) reported in their studies
the protective effect of TS 3R variant in childhood leukaemia
patients. In our study we observed that the TS 3R2R (OR =
0.79; 95% CI, 0.22-2.92) and 2R2R variants (OR = 0.39; 95%
CI, 0.09-1.58) to be associated with a decreased risk of
childhood leukaemia in the Malaysian population. An
interaction between TS 2R variant and SHMT 1420 CC was
observed in increasing the risk of malignant lymphoma (17),
while decreased risk of leukaemia in adults was observed
in TS 3R variant and SHMT1 interaction (16). However, in
our study, we could not confirm the protective effect of
interaction between 3R variant and SHMT1 gene. Futher
studies are needed to elucidate the effect of TS gene
polymorphisms.
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SHMT1 gene catalyzes the reversible conversion of
serine and tetrahydofolate (THF) to glycine and methylene-
THF providing the cells with most of the one-carbon units
reqiured for the synthesis of thymidine, purines, cholines
and methionine (32). In our study, the SHMT1 allele-T
variant showed a higher distribution (56%) compared with
SHMT allele-C variant. Both the Japanese (17) and British
populations (16) had a higher proportion with the SHMT
allele-C variant. We also observed an increased risk of
leukaemia in for the SHMT1 CT variant (OR = 2.33; 95 % CI,
0.56-9.64) and SHMT1 TT (OR = 13.7; 95% CI, 3.24-58.05),
an observation which is different from the British and
Japanese studies which showed decreased risk in adult
leukaemia for the same variant (16). This might be due to
the different ethnic composition of the Malaysian
population compared to Japanese and Caucasian
populations.
MTHFD1 G1958A is also known as tri-functional
enzyme that converts THF in three different ways (34).
Even though the function and the relationship of MTHFD1
gene with the risk of childhood leukaemia are still unclear,
we believe that MTHFD1, which plays a role in the
formation of purines through formyl-THF (34) formation
also play a role in leukaemogenesis as do other folate-
related gene polymorphisms. The frequency of MTHFD1
1958 GG variant in childhood leukaemia in the Malaysian
population is 51.9% in comparison to those with neural
tube defects (17.6%) in the Italian population (15). In this
study, the MTHFD1 1958 GA variant (OR = 0.42; 95% CI,
0.20-0.90; p = 0.03) showed decreased risk of childhood
leukaemia. However, due to limited number of references to
support our finding, the function of MTHFD1 remains
questionable.
The MTR gene plays an essential role in determining
the homosisteine level in methtionine metabolism. It plays
a critical role in maintaining adequate intracellular S-
adenosyl-methionine (SAM) levels for DNA methylation
and it also has a tumour suppressor effect. The MTR
polymorphism A2576C converts an aspartic acid to a glycine
residue and has been predicted to alter enzyme activity
that may affect DNA methylation process (35). MTR
requires activation by MTRR (36). The elevated
homocysteine level causes DNA methylation which is
involved in carcinogenesis (37). In this study, the
frequencies of MTR gene polymorphisms were not
significantly different between childhood leukaemia
patients and controls and this is similar to that reported by
Gemmati et al in 2004 (2). In the same report, the MTRR 66
AG genotype was found to be most common in the Italian
population which is similar to the observation in our study
with a 75.8% distribution of the genotype. We also observed
an interaction between MTR 2756 AA and MTRR 66 GG
variants in decreasing leukaemia risk (OR = 0.04; 95% CI,
0.007-0.3).
Even though statistical analysis show that our
hypothesis of the involvement of folate-related genes in
the development of leukaemia in Malaysian childhood is
valid, low frequency distribution in carrier alleles and mutant
alleles might have cause some discrepancies. Results
observed in our study may have been affected by the ethnic
composition of our subjects. However, we were not able to
study the relationship between ethnicity and folate-related
gene polymorphisms as the distribution ratio of the 3 ethnic
groups among our study subjects was not evenly
distributed (Malay: Chinese : Indian = 11 : 1.2 : 1).
In conclusion, we observed different distribution of
folate-related gene polymorphisms in the Malaysian
population and compared this distribution to other
populations in other regions. In this study, the relationship
of these genes with the risk of childhood leukaemia in the
Malaysian population was observed, increasing our
understanding of the function and interaction of these
genes in folate metabolism pathway.
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